{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T23:36:49Z","timestamp":1772494609489,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009128","name":"Research for Patient Benefit Programme","doi-asserted-by":"publisher","award":["PB-PG-0418-20029"],"award-info":[{"award-number":["PB-PG-0418-20029"]}],"id":[{"id":"10.13039\/501100009128","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Targeted beta-blockade after severe traumatic brain injury may reduce secondary brain injury by attenuating the sympathoadrenal response. The potential role and optimal dosage for esmolol, a selective, short-acting, titratable beta-1 beta-blocker, as a safe, putative early therapy after major traumatic brain injury has not been assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a single-center, open-label dose-finding study using an adaptive model-based design. Adults (18 years or older) with severe traumatic brain injury and intracranial pressure monitoring received esmolol within 24 h of injury to reduce their heart rate by 15% from baseline of the preceding 4 h while ensuring cerebral perfusion pressure was maintained above 60 mm Hg. In cohorts of three, the starting dosage and dosage increments were escalated according to a prespecified plan in the absence of dose-limiting toxicity. Dose-limiting toxicity was defined as failure to maintain cerebral perfusion pressure, triggering cessation of esmolol infusion. The primary outcome was the maximum tolerated dosage schedule of esmolol, defined as that associated with less than 10% probability of dose-limiting toxicity. Secondary outcomes include 6-month mortality and 6-month extended Glasgow Outcome Scale score.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sixteen patients (6 [37.5%] female patients; mean age 36 years [standard deviation 13 years]) with a median Glasgow Coma Scale score of 6.5 (interquartile range 5\u20137) received esmolol. The optimal starting dosage of esmolol was 10 \u03bcg\/kg\/min, with increments every 30 min of 5 \u03bcg\/kg\/min, as it was the highest dosage with less than 10% estimated probability of dose-limiting toxicity (7%). All-cause mortality was 12.5% at 6 months (corresponding to a standardized mortality ratio of 0.63). One dose-limiting toxicity event and no serious adverse hemodynamic effects were seen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Esmolol administration, titrated to a heart rate reduction of 15%, is feasible within 24 h of severe traumatic brain injury. The probability of dose-limiting toxicity requiring withdrawal of esmolol when using the optimized schedule is low.<\/jats:p>\n                <jats:p><jats:italic>Trial registrationI<\/jats:italic> SRCTN, ISRCTN11038397, registered retrospectively January 7, 2021 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.isrctn.com\/ISRCTN11038397\">https:\/\/www.isrctn.com\/ISRCTN11038397<\/jats:ext-link>).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12028-024-02029-8","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T23:02:51Z","timestamp":1719874971000},"page":"1009-1019","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early Intravenous Beta-Blockade with Esmolol in Adults with Severe Traumatic Brain Injury: A Phase 2a Intervention Design Study"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3407-6762","authenticated-orcid":false,"given":"Matt","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kati","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Baumer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clodagh","family":"Beattie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aravind","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Culliford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gareth L.","family":"Ackland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony E.","family":"Pickering","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"key":"2029_CR1","unstructured":"Brain Trauma Foundation. Guidelines for the management of severe traumatic brain injury, fourth edition (2016). https:\/\/braintrauma.org\/guidelines\/guidelines-for-the-management-of-severe-tbi-4th-ed#\/"},{"key":"2029_CR2","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s00134-019-05805-9","volume":"45","author":"G Hawryluck","year":"2019","unstructured":"Hawryluck G, Aguilera S, Buki A, et al. A management algorithm for patients with intracranial pressure monitoring: the Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC). Intensive Care Med. 2019;45:1783\u201394. https:\/\/doi.org\/10.1007\/s00134-019-05805-9.","journal-title":"Intensive Care Med"},{"key":"2029_CR3","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00134-022-06702-4","volume":"48","author":"G Meyfroid","year":"2022","unstructured":"Meyfroid G, Bouzat P, Casaer M, et al. Management of moderate to severe traumatic brain injury: an update for the intensivist. Intensive Care Med. 2022;48:649\u201366. https:\/\/doi.org\/10.1007\/s00134-022-06702-4.","journal-title":"Intensive Care Med"},{"key":"2029_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.emc.2022.09.014","volume":"41","author":"V Salasky","year":"2023","unstructured":"Salasky V, Chang W. Neurotrauma update. Emerg Med Clin North Am. 2023;41:19\u201333. https:\/\/doi.org\/10.1016\/j.emc.2022.09.014.","journal-title":"Emerg Med Clin North Am"},{"key":"2029_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1124\/jpet.121.001023","volume":"382","author":"M Hiskens","year":"2022","unstructured":"Hiskens M. Targets of neuroprotection and review of pharmacological interventions in traumatic brain injury. J Pharmacol Exper Ther. 2022;382:149\u201366. https:\/\/doi.org\/10.1124\/jpet.121.001023.","journal-title":"J Pharmacol Exper Ther"},{"key":"2029_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/bja\/85.1.109","volume":"85","author":"J Desborough","year":"2000","unstructured":"Desborough J. The stress response to trauma and surgery. Br J Anaesth. 2000;85:109\u201317. https:\/\/doi.org\/10.1093\/bja\/85.1.109.","journal-title":"Br J Anaesth"},{"key":"2029_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13054-017-1605-5","volume":"21","author":"P Johansson","year":"2017","unstructured":"Johansson P, Stensballe J, Ostrowski S. Shock induced endotheliopathy (SHINE) in acute critical illness\u2014a unifying pathophysiologic mechanism. Crit Care. 2017;21:25. https:\/\/doi.org\/10.1186\/s13054-017-1605-5.","journal-title":"Crit Care"},{"key":"2029_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/bja\/aem131","volume":"99","author":"C Werner","year":"2007","unstructured":"Werner C, Engelhard K. Pathophysiology of traumatic brain injury. Br J Anaesth. 2007;99:4\u20139. https:\/\/doi.org\/10.1093\/bja\/aem131.","journal-title":"Br J Anaesth"},{"key":"2029_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12974-016-0500-3","volume":"13","author":"A Di Battista","year":"2016","unstructured":"Di Battista A, Rhind S, Hutchison M, et al. Inflammatory cytokine and chemokine profiles are associated with patient outcome and the hyperadrenergic state following acute brain injury. J Neuroinflammation. 2016;13:40. https:\/\/doi.org\/10.1186\/s12974-016-0500-3.","journal-title":"J Neuroinflammation"},{"key":"2029_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13054-017-1620-6","volume":"21","author":"S Rizoli","year":"2017","unstructured":"Rizoli S, Jaja B, Di Battista A, et al. Catecholamines as outcome markers in isolated traumatic brain injury: the COMA-TBI study. Crit Care. 2017;21:37. https:\/\/doi.org\/10.1186\/s13054-017-1620-6.","journal-title":"Crit Care"},{"issue":"3 Suppl.","key":"2029_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/SHK.0000000000000642","volume":"46","author":"A Di Battista","year":"2016","unstructured":"Di Battista A, Rizoli S, Lejnieks B, et al. Sympathoadrenal activation is associated with acute traumatic coagulopathy and endotheliopathy in isolated brain injury. Shock. 2016;46(3 Suppl.):96\u2013103. https:\/\/doi.org\/10.1097\/SHK.0000000000000642.","journal-title":"Shock"},{"key":"2029_CR12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/TA.0b013e31819388be","volume":"66","author":"E Ley","year":"2009","unstructured":"Ley E, Scehnet J, Park R, et al. The in vivo effect of propranolol on cerebral perfusion and hypoxia after traumatic brain injury. J Trauma. 2009;66:154\u20139. https:\/\/doi.org\/10.1097\/TA.0b013e31819388be.","journal-title":"J Trauma"},{"key":"2029_CR13","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/TA.0000000000003537","volume":"92","author":"A Lopez","year":"2022","unstructured":"Lopez A, ElSaadani M, Jacovides C, et al. Beta blockade in TBI: Dose dependent reductions in BBB leukocyte mobilization and permeability in vivo. J Trauma Acute Care Surg. 2022;92:781\u201391. https:\/\/doi.org\/10.1097\/TA.0000000000003537.","journal-title":"J Trauma Acute Care Surg"},{"key":"2029_CR14","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.bja.2019.07.017","volume":"123","author":"W Armstead","year":"2019","unstructured":"Armstead W, Vavilala M. Propranolol protects cerebral autoregulation and reduces hippocampal neuronal cell death through inhibition of interleukin-6 upregulation after traumatic brain injury in pigs. Br J Anaesth. 2019;123:610\u20137. https:\/\/doi.org\/10.1016\/j.bja.2019.07.017.","journal-title":"Br J Anaesth"},{"key":"2029_CR15","doi-asserted-by":"publisher","first-page":"e000307","DOI":"10.1136\/tsaco-2019-000307","volume":"4","author":"T Schroeppel","year":"2019","unstructured":"Schroeppel T, Sharpe J, Shahan C, et al. Beta-adrenergic blockade for attenuation of catecholamine surge after traumatic brain injury: a randomized pilot trial. Trauma Surg Acute Care Open. 2019;4:e000307.","journal-title":"Trauma Surg Acute Care Open"},{"key":"2029_CR16","doi-asserted-by":"publisher","first-page":"514","DOI":"10.4103\/sja.SJA_33_18","volume":"12","author":"M Ammar","year":"2018","unstructured":"Ammar M, Hussein N. Using propranolol in traumatic brain injury to reduce sympathetic storm phenomenon: a prospective randomized clinical trial. Saudi J Anaesth. 2018;12:514\u201320.","journal-title":"Saudi J Anaesth"},{"key":"2029_CR17","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1007\/s00268-020-05391-8","volume":"44","author":"H Khalili","year":"2020","unstructured":"Khalili H, Ahl R, Paydar S, et al. Beta-blocker therapy in severe traumatic brain injury: a prospective randomized controlled trial. World J Surg. 2020;44:1844\u201353. https:\/\/doi.org\/10.1007\/s00268-020-05391-8.","journal-title":"World J Surg"},{"issue":"Suppl. 12","key":"2029_CR18","doi-asserted-by":"publisher","first-page":"A81","DOI":"10.1097\/01.ccm.0000390903.16849.8c","volume":"38","author":"H Khaber","year":"2010","unstructured":"Khaber H, Fayed A, Khattab A. A prospective randomized study comparing metoprolol to placebo in the management of severe traumatic brain injury. Crit Care Med. 2010;38(Suppl. 12):A81. https:\/\/doi.org\/10.1097\/01.ccm.0000390903.16849.8c.","journal-title":"Crit Care Med"},{"key":"2029_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13054-023-04479-6","volume":"27","author":"M Nordness","year":"2023","unstructured":"Nordness M, Maiga A, Wilson L, et al. Effect of propranolol and clonidine after severe traumatic brain injury: a pilot randomized clinical trial. Crit Care. 2023;27:228. https:\/\/doi.org\/10.1186\/s13054-023-04479-6.","journal-title":"Crit Care"},{"key":"2029_CR20","doi-asserted-by":"publisher","first-page":"e121225","DOI":"10.5812\/ans.121425","volume":"9","author":"T Zarei","year":"2022","unstructured":"Zarei T, Ahmadi A, Najafi A, et al. Intravenous esmolol for intracranial pressure reduction after traumatic brain injury. Arch Neurosci. 2022;9:e121225. https:\/\/doi.org\/10.5812\/ans.121425.","journal-title":"Arch Neurosci"},{"key":"2029_CR21","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1177\/00031348221101583","volume":"89","author":"I Zagales","year":"2023","unstructured":"Zagales I, Selvakumar S, Ngatuvai M, et al. Beta-blocker therapy in patients with severe traumatic brain injury: a systematic review and meta-analysis. Am Surg. 2023;89:2020\u20139. https:\/\/doi.org\/10.1177\/00031348221101583.","journal-title":"Am Surg"},{"key":"2029_CR22","doi-asserted-by":"publisher","first-page":"e001051","DOI":"10.1136\/tsaco-2022-001051","volume":"8","author":"S Hart","year":"2020","unstructured":"Hart S, Lannon M, Chen A, Martyniuk A, Sharma S, Engels P. Beta blockers in traumatic brain injury: a systematic review and meta-analysis. Trauma Surg Acute Care Open. 2020;8:e001051. https:\/\/doi.org\/10.1136\/tsaco-2022-001051.","journal-title":"Trauma Surg Acute Care Open"},{"key":"2029_CR23","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1080\/01616412.2020.1866385","volume":"43","author":"W Florez-Perdomo","year":"2021","unstructured":"Florez-Perdomo W, Torres E, Serrato A, Janjua T, Joaquim A, Moscote-Salazar L. A systematic review and meta-analysis on effect of beta-blockers in severe traumatic brain injury. Neurol Res. 2021;43:609\u201315. https:\/\/doi.org\/10.1080\/01616412.2020.1866385.","journal-title":"Neurol Res"},{"key":"2029_CR24","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1097\/SLA.0000000000002286","volume":"266","author":"A Alali","year":"2017","unstructured":"Alali A, Mukherjee K, McCredie V, et al. Beta-blockers and traumatic brain injury: a systematic review, meta-analysis and Eastern Association for the Surgery of Trauma guideline. Ann Surg. 2017;266:952\u201361.","journal-title":"Ann Surg"},{"key":"2029_CR25","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jcrc.2017.05.035","volume":"41","author":"Z Chen","year":"2017","unstructured":"Chen Z, Tan L, Xu X, Wei X, Wen L, Xie Q. Therapeutic effect of beta-blocker in patients with traumatic brain injury: a systematic review and meta-analysis. J Crit Care. 2017;41:240\u20136.","journal-title":"J Crit Care"},{"key":"2029_CR26","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1097\/TA.0000000000001747","volume":"90","author":"H Ding","year":"2021","unstructured":"Ding H, Liao L, Zheng X, et al. \u03b2-blockers for traumatic brain injury: a systematic review and meta-analysis. J Trauma Acute Care Surg. 2021;90:1077\u201385. https:\/\/doi.org\/10.1097\/TA.0000000000001747.","journal-title":"J Trauma Acute Care Surg"},{"key":"2029_CR27","doi-asserted-by":"publisher","first-page":"190","DOI":"10.2165\/00003088-199528030-00002","volume":"28","author":"D Wiest","year":"1995","unstructured":"Wiest D. Esmolol: A review of its therapeutic efficacy and pharmacokinetic characteristics. Clin Pharmacokinet. 1995;28:190\u2013202. https:\/\/doi.org\/10.2165\/00003088-199528030-00002.","journal-title":"Clin Pharmacokinet"},{"key":"2029_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.brainres.2010.04.079","volume":"1343","author":"T Goyagi","year":"2010","unstructured":"Goyagi T, Horiguchi T, Nishikawa T, Tobe Y. Post-treatment with selective beta-1 adrenoceptor antagonists provides neuroprotection against transient focal ischaemia in rats. Brain Res. 2010;1343:213\u20137. https:\/\/doi.org\/10.1016\/j.brainres.2010.04.079.","journal-title":"Brain Res"},{"key":"2029_CR29","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1213\/ANE.0b013e3181cdb06b","volume":"110","author":"S Unehara","year":"2010","unstructured":"Unehara S, Goyagi T, Nishikawa T, Tobe Y, Masaki Y. Esmolol and landiolol, selective beta1-adrenoceptor antagonists, provide neuroprotection against spinal cord ischaemia and reperfusion in rats. Anesth Analg. 2010;110:1133\u20137. https:\/\/doi.org\/10.1213\/ANE.0b013e3181cdb06b.","journal-title":"Anesth Analg"},{"key":"2029_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/1553350614532534","volume":"22","author":"Y Kim","year":"2015","unstructured":"Kim Y, Hwang W, Cho M, Her Y, Ahn S, Lee J. The effects of intraoperative esmolol administration on perioperative inflammatory responses in patients undergoing laparoscopic gastrectomy: a dose response study. Surg Innov. 2015;22:177\u201382. https:\/\/doi.org\/10.1177\/1553350614532534.","journal-title":"Surg Innov"},{"key":"2029_CR31","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1097\/00000539-200112000-00039","volume":"93","author":"J Johansen","year":"2001","unstructured":"Johansen J. Esmolol promotes electroencephalographic burst suppression during propofol\/alfentanil anesthesia. Anesth Analg. 2001;93:1526\u201331. https:\/\/doi.org\/10.1097\/00000539-200112000-00039.","journal-title":"Anesth Analg"},{"key":"2029_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/00000542-200501000-00010","volume":"102","author":"W Heinke","year":"2005","unstructured":"Heinke W, Zysset S, Hund-Georgiadis M, Olthoff D, von Cramon D. The effect of esmolol on cerebral blood flow, cerebral vasoreactivity, and cognitive performance: a functional magnetic resonance imaging study. Anesthesiology. 2005;102:41\u201350. https:\/\/doi.org\/10.1097\/00000542-200501000-00010.","journal-title":"Anesthesiology"},{"key":"2029_CR33","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/BF03021600","volume":"52","author":"S Saito","year":"2005","unstructured":"Saito S, Nishihara F, Akihiro T, et al. Landiolol and esmolol prevent tachycardia without altering cerebral blood flow. Can J Anaesth. 2005;52:1027\u201334. https:\/\/doi.org\/10.1007\/BF03021600.","journal-title":"Can J Anaesth"},{"key":"2029_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1399-6576.1995.tb04075.x","volume":"39","author":"B Asgeirsson","year":"1995","unstructured":"Asgeirsson B, Grande P, Nordstrom C, Berntman L, Messeter K, Ryding E. Effects of hypotensive treatment with alpha 2-agonist and beta 1-antagonist on cerebral haemodynamics in severely head injured patients. Acta Anaesthesiol Scand. 1995;39:347\u201351. https:\/\/doi.org\/10.1111\/j.1399-6576.1995.tb04075.x.","journal-title":"Acta Anaesthesiol Scand"},{"key":"2029_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/archdischild-2019-316931","volume":"106","author":"G Millen","year":"2021","unstructured":"Millen G, Yap C. Adaptive trial designs: what is the continual reassessment method? Arch Dis Child Educ Pract. 2021;106:175\u20137. https:\/\/doi.org\/10.1136\/archdischild-2019-316931.","journal-title":"Arch Dis Child Educ Pract"},{"key":"2029_CR36","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1200\/JCO.2013.54.6051","volume":"32","author":"A Iasonos","year":"2014","unstructured":"Iasonos A, O\u2019Quigley J. Adaptive dose-finding studies: a review of model-guided phase 1 clinical trials. J Clin Oncol. 2014;32:2505\u201311. https:\/\/doi.org\/10.1200\/JCO.2013.54.6051.","journal-title":"J Clin Oncol"},{"key":"2029_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-023-01755-9","author":"M Thomas","year":"2023","unstructured":"Thomas M, Hayes K, White P, et al. Early intravenous beta-blockade with esmolol in adults with severe traumatic brain injury (EBB-TBI): Protocol for a Phase 2a intervention design study. Neurocrit Care. 2023. https:\/\/doi.org\/10.1007\/s12028-023-01755-9.","journal-title":"Neurocrit Care"},{"key":"2029_CR38","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jama.2013.278477","volume":"310","author":"A Morelli","year":"2013","unstructured":"Morelli A, Ertmer C, Westphal M, et al. Effect of heart rate control with esmolol on haemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013;310:1683\u201391. https:\/\/doi.org\/10.1001\/jama.2013.278477.","journal-title":"JAMA"},{"key":"2029_CR39","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1227\/NEU.0000000000000533","volume":"75","author":"R Raj","year":"2014","unstructured":"Raj R, Siironen J, Skrifvars M, Hernesniemi J, Kivisaari R. Predicting outcome in traumatic brain injury: development of a novel computerized tomography classification system (Helsinki computerized tomography score). Neurosurgery. 2014;75:632\u201346. https:\/\/doi.org\/10.1227\/NEU.0000000000000533.","journal-title":"Neurosurgery"},{"key":"2029_CR40","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.wneu.2017.02.072","volume":"101","author":"S Yao","year":"2017","unstructured":"Yao S, Song J, Li S, et al. Helsinki computed tomography scoring system can independently predict long-term outcome in traumatic brain injury. World Neurosurg. 2017;101:528\u201333. https:\/\/doi.org\/10.1016\/j.wneu.2017.02.072.","journal-title":"World Neurosurg"},{"key":"2029_CR41","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S1474-4422(19)30232-7","volume":"18","author":"E Steyerberg","year":"2019","unstructured":"Steyerberg E, Wiegers E, Sewalt C, et al. Case-mix, care pathways, and outcomes in patients with traumatic brain injury in CENTER-TBI: a European prospective, multicentre, longitudinal, cohort study. Lancet Neurol. 2019;18:923\u201334. https:\/\/doi.org\/10.1016\/S1474-4422(19)30232-7.","journal-title":"Lancet Neurol"},{"key":"2029_CR42","doi-asserted-by":"publisher","first-page":"e012197","DOI":"10.1136\/bmjopen-2016-012197","volume":"24","author":"T Lawrence","year":"2016","unstructured":"Lawrence T, Helmy A, Bouamra O, et al. Traumatic brain injury in England and Wales: prospective audit of epidemiology, complications and standardised mortality. BMJ Open. 2016;24:e012197. https:\/\/doi.org\/10.1136\/bmjopen-2016-012197.","journal-title":"BMJ Open"},{"key":"2029_CR43","doi-asserted-by":"publisher","unstructured":"Ley E, Leonard S, Barmparas G et al. for the Beta Blockers TBI Study Group Collaborators. Beta blockers in critically ill patients with traumatic brain injury: results from a multicentre, prospective, observational American Association for the Surgery of Trauma study. J Trauma Acute Care Surg. 2018; 84: 234\u2013244. https:\/\/doi.org\/10.1097\/TA.0000000000001747","DOI":"10.1097\/TA.0000000000001747"},{"key":"2029_CR44","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1213\/ANE.0000000000005949","volume":"135","author":"C Toro","year":"2022","unstructured":"Toro C, Ohnuma T, Komisarow J, et al. Early vasopressor utilization strategies and outcomes in critically ill patients with severe traumatic brain injury. Anesth Analg. 2022;135:1245\u201352. https:\/\/doi.org\/10.1213\/ANE.0000000000005949.","journal-title":"Anesth Analg"},{"key":"2029_CR45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/TA.0b013e31815eb15a","volume":"64","author":"A Salim","year":"2008","unstructured":"Salim A, Hadjizacharia P, Brown C, et al. Significance of troponin elevation after severe traumatic brain injury. J Trauma. 2008;64:46\u201352. https:\/\/doi.org\/10.1097\/TA.0b013e31815eb15a.","journal-title":"J Trauma"},{"key":"2029_CR46","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/TA.0000000000000104","volume":"76","author":"T Schroeppel","year":"2014","unstructured":"Schroeppel T, Sharpe J, Magnotti L, et al. Traumatic brain injury and beta-blockers: not all drugs are created equal. J Trauma Acute Care Surg. 2014;76:504\u20139. https:\/\/doi.org\/10.1097\/TA.0000000000000104.","journal-title":"J Trauma Acute Care Surg"},{"key":"2029_CR47","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/BF01708961","volume":"20","author":"B Asgeirsson","year":"1994","unstructured":"Asgeirsson B, Grande P, Nordstrom C. A new therapy of post-trauma brain oedema based on haemodynamic principles for brain volume regulation. Intensive Care Med. 1994;20:260\u20137. https:\/\/doi.org\/10.1007\/BF01708961.","journal-title":"Intensive Care Med"},{"key":"2029_CR48","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000006869","author":"S Liu","year":"2024","unstructured":"Liu S, Kelly-Hedrick M, Komisarow J, et al. Association of early dexmedetomidine utilization with clinical outcomes after moderate-severe traumatic brain injury: a retrospective cohort study. Anesth Analg. 2024. https:\/\/doi.org\/10.1213\/ANE.0000000000006869.","journal-title":"Anesth Analg"},{"key":"2029_CR49","doi-asserted-by":"publisher","first-page":"965661","DOI":"10.3389\/fphar.2022.965661","volume":"13","author":"Y Hu","year":"2022","unstructured":"Hu Y, Zhou H. Zhang H et al The neuroprotective effect of dexmedetomidine and its mechanism. Front Pharmacol. 2022;13:965661. https:\/\/doi.org\/10.3389\/fphar.2022.965661.","journal-title":"Front Pharmacol"},{"key":"2029_CR50","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/SHK.0000000000000636","volume":"46","author":"T Loftus","year":"2016","unstructured":"Loftus T, Efron P, Moldawer L, Mohr A. \u03b2-blockade use for traumatic injuries and immunomodulation: a review of proposed mechanisms and clinical evidence. Shock. 2016;46:341\u201351. https:\/\/doi.org\/10.1097\/SHK.0000000000000636.","journal-title":"Shock"},{"key":"2029_CR51","doi-asserted-by":"publisher","first-page":"e0280796","DOI":"10.1371\/journal.pone.0280796","volume":"18","author":"N von Steinbuechel","year":"2023","unstructured":"von Steinbuechel N, Rauen K, Covic A, et al. Sensitivity of outcome instruments in a priori selected patient groups after traumatic brain injury: results from the CENTER-TBI study. PLoS ONE. 2023;18:e0280796. https:\/\/doi.org\/10.1371\/journal.pone.0280796.","journal-title":"PLoS ONE"},{"key":"2029_CR52","doi-asserted-by":"publisher","first-page":"713100","DOI":"10.3389\/fphar.2022.71310","volume":"13","author":"J Navarro","year":"2022","unstructured":"Navarro J, Mejia L, Robertson C. A precision medicine agenda in traumatic brain injury. Front Pharmacol. 2022;13:713100. https:\/\/doi.org\/10.3389\/fphar.2022.71310.","journal-title":"Front Pharmacol"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-024-02029-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-024-02029-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-024-02029-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T18:02:48Z","timestamp":1732644168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-024-02029-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2029"],"URL":"https:\/\/doi.org\/10.1007\/s12028-024-02029-8","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]},"assertion":[{"value":"31 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"North Bristol NHS Trust (MT and KH); University of the West of England, Bristol (PW); Queen Mary University of London (GLA); and University of Bristol (LC and AEP) received funding from the National Institute for Health and Care Research for this study. AR, CB, and TB have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study described in this article adheres to the ethical guidelines laid down in the Declaration of Helsinki (1964), has Health Research Authority approval, and seeks to obtain informed consent from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval\/Informed Consent"}}]}}